Long-term retention of golimumab treatment in clinical practice in a large cohort of patients with rheumatoid arthritis, axial spondyloarthritis and psoriatic arthritis

To assess the golimumab retention rate during up to 8 years of follow up, and any associated factors. Retrospective analysis of the BIOBADASER (Spanish registry of biological drugs) database, assessing all adults who had ever started golimumab.

Detalles Bibliográficos
Autores: Pombo-Suárez, Manuel, Seoane-Mato, Daniel|||0000-0001-5430-039X, Díaz-González, Federico|||0000-0002-4139-9295, Cea-Calvo, Luis, Sánchez-Alonso, Fernando, Sánchez-Jareño, Marta, Jovani, Vega|||0000-0001-8529-4551, García-Magallón, Blanca, Martínez-González, Olga, Campos-Fernández, Cristina, Manero, Javier, Diaz-Torne, Cesar|||0000-0001-6275-7699, Bohórquez, Cristina, Ros-Vilamajó, Inmaculada, Pérez-Vera, Yanira, Castrejón, Isabel
Tipo de recurso: artículo
Fecha de publicación:2023
País:España
Institución:Universitat Autònoma de Barcelona
Repositorio:Dipòsit Digital de Documents de la UAB
Idioma:inglés
OAI Identifier:oai:ddd.uab.cat:302856
Acceso en línea:https://ddd.uab.cat/record/302856
https://dx.doi.org/urn:doi:10.1002/msc.1684
Access Level:acceso abierto
Palabra clave:Axial spondyloarthritis
Golimumab
Psoriatic arthritis
Rheumatoid arthritis
Treatment retention
Descripción
Sumario:To assess the golimumab retention rate during up to 8 years of follow up, and any associated factors. Retrospective analysis of the BIOBADASER (Spanish registry of biological drugs) database, assessing all adults who had ever started golimumab.

Similares en LA Referencia